#United States #Bethesda #DCVax #Advent BioServices #NWBio

Northwest Biotherapeutics Completes Acquisition of Advent BioServices

Bethesda, MD, October 24, 2025 — Northwest Biotherapeutics, Inc. (OTCQB:NWBO), a pioneering biotechnology firm focused on personalized immune therapies for cancer, announced today the successful closure of its acquisition of Advent BioServices Ltd. Advent is now a wholly owned subsidiary of NWBio, marking a significant step forward in the company’s operational strategy.

This acquisition is strategically aimed at improving efficiency and scaling operations to enhance the development and delivery of NWBio's flagship product, the DCVax® personalized immune therapy. The integration of Advent's capabilities is expected to lead to a more streamlined workflow across various operational facets.

Details of the Acquisition

The acquisition allows NWBio to integrate Advent's technologies, expertise, and intellectual property into its existing framework. This integration is anticipated to yield a fully combined platform with optimized supply chain and facility management. Specifically, NWBio plans to close its GMP facility in London and redirect resources to its Sawston, UK establishment, while also expanding manufacturing capacity within the United States.

One of the key benefits of this acquisition is the receipt of Advent's fixed assets, including crucial cryostorage and other high-value equipment acquired over the years. Additionally, this transfer includes various intellectual properties and intangible assets previously held by Advent, further strengthening NWBio’s capabilities.

In alignment with the acquisition, NWBio will not issue any new securities. Instead, 19 million NWBio securities (comprising 13.5 million shares and 5.5 million options) previously allocated to Advent as payment for services will revert back to NWBio.

The financial structure of the deal involves an initial payment of £1.4 million, along with installments tied to accounts payable for existing contracts. Payments will commence 90 days following the closing of the deal, thus solidifying the financial timeline for the acquisition.

CEO's Perspective

Linda Powers, CEO of Northwest Biotherapeutics, expressed enthusiasm regarding this acquisition, stating, “We are excited to have completed the necessary conditions for closing the acquisition of Advent, and to be moving into position for potential significant scale-up. We believe this integration can also help accelerate the development of additional applications and next-generation versions of our technologies.”

This sentiment outlines the company’s strategic vision, aiming to leverage the combined expertise and intellectual resources to create a dominant industry force.

About Northwest Biotherapeutics

Founded with the vision of transforming cancer care, Northwest Biotherapeutics specializes in developing personalized immunotherapy products designed to treat cancer more effectively than existing therapies and without the toxicities associated with traditional chemotherapies. The company’s lead program, DCVax®-L, targets glioblastoma (GBM), a highly aggressive form of brain cancer. Following the successful completion of a Phase III trial involving 331 patients, the company has submitted its Marketing Authorization Application (MAA) in the UK, which is currently under scrutiny.

In addition to its glioblastoma efforts, NWBio is also advancing DCVax®-Direct, aimed at treating inoperable solid tumor cancers, having progressed through a Phase I trial and anticipating Phase II trials soon. The company also has previous experience with DCVax-L in advanced ovarian cancer trials partnered with the University of Pennsylvania.

As they move forward with this acquisition, Northwest Biotherapeutics remains focused on innovative strategies that prioritize patient care, driving them closer to being a leader in cancer treatment.

Disclaimer

This article contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. While the company aims to progress its objectives, actual results may differ due to various risks outlined in their SEC filings. Readers should not rely solely on forward-looking statements, as they are subject to change based on market conditions and other factors.